Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus
chemotherapy) to reduce treatment intensity and improve long-term quality of life while
maintaining very high cure rates.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins